These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment. Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459 [No Abstract] [Full Text] [Related]
45. Drug maker's vow to donate cancer medicine falls short. Strom S; Fleischer-Black M N Y Times Web; 2003 Jun; ():A1, C7. PubMed ID: 14621708 [No Abstract] [Full Text] [Related]
46. [Current progress in therapy of malignant diseases]. Hiddemann W; Heinemann V Dtsch Med Wochenschr; 2005 Aug; 130(31-32):1837-40. PubMed ID: 16052450 [No Abstract] [Full Text] [Related]
47. Initial experience with the human tumor stem cell assay system: potential and problems. Von Hoff DD; Harris GJ; Johnson G; Glaubiger D Prog Clin Biol Res; 1980; 48():113-24. PubMed ID: 7208514 [No Abstract] [Full Text] [Related]
48. Targeted therapies: the answer to individualized treatment? Hutchinson L Nat Clin Pract Oncol; 2007 Jun; 4(6):323. PubMed ID: 17534387 [No Abstract] [Full Text] [Related]
59. A progression puzzle. Bernards R; Weinberg RA Nature; 2002 Aug; 418(6900):823. PubMed ID: 12192390 [No Abstract] [Full Text] [Related]
60. Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity. Koehler M; Donnelly ET; Kalanovic D; Dagher R; Rothenberg ML Ann Oncol; 2016 Jul; 27(7):1342-8. PubMed ID: 27029709 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]